We have read with interest the paper by Uz 1 and co-workers about the role of the local haematopoietic renin-angiotensin system (RAS) in myeloid versus lymphoid haematological neoplastic disorders. Previous data supported the existence of an endogenous RAS in some local tissues. Locally produced angiotensin exerts autocrine/paracrine influences. 2 It has been suggested that the presence of RAS in the bone marrow might affect cellular proliferation and differentiation in physiological or pathological states. 3 Consistent with this theory, it has been demonstrated that myeloid blast cells contain renin in their cytosol 4 and that bone marrow blast cells from some types of acute myeloid leukaemia (AML) express renin. 5 We had previously investigated the expression of renin in bone marrow cells of patients with haematological malignancies and found significant renin expression in cells from patients with AML, but no expression in normal bone marrow from healthy donors. 6 Also we have evaluated the clinical relevance of renin gene expression in the prognosis and outcome of renin positive AML patients. 7 Uz 1 et al. have studied the renin expression in 46 patients, with lymphoid (n=30) or myeloid (n=16) haematological neoplasm and they have reported that 77% of AML and 100% of acute lymphoid leukaemia (ALL) patients were renin positive. This renin expression prevalence is higher than that previously described by our group (41%-47.2% in AML) 6, 7 and it could be caused by the different methodology used.
We also demonstrated that renin expression is related to disease activity. We analysed renin gene expression by realtime PCR in 76 samples from patients with AML, with follow-up of positive patients. We showed that renin expression disappeared with haematological remission and returned with relapse. Real-time PCR assay might become the best option for the follow-up of the renin positive patients without other molecular markers of minimal residual disease. 7, 8 Our results suggest that the subgroup of renin-positive AML patients might have a poorer outcome and a higher relapse rate, although there were no significant differences. 7 We believe that the RAS system plays an important role in normal and pathological haematopoiesis although the molecular pathways involved still have not yet been fully understood. 3 ACE inhibitors and AT1 receptor antagonist exert an antiproliferative and apoptotic activity on leukaemic cells. 9 These results offer a new possible treatment mechanism in some AML, since these drugs could very well have an anti-neoplastic role either associated to other drugs or by themselves, offering as well a new area of clinical research. 10 We agree with the author in that the activities of local RAS may differ in distinct disease states such as in leukaemia and lymphomas, 1 and also between AML and ALL.
It could be interesting to compare renin expression in ALL patients with or without active disease and also analyse the evolution of renin expression in ALL during the outcome of the disease.
